Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.36 |
| ▸ | MMP9 | P14780 | 5/20 | 0.36 |
| ▸ | MMP8 | P22894 | 4/20 | 0.36 |
| ▸ | MMP13 | P45452 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 5/20 | 0.34 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13708993 | 1.00 | MMP2 (0.36) | MMP2MMP9MMP8MMP13CNR1 | |
| SCHEMBL4511675 | 1.00 | MMP2 (0.36) | MMP2MMP9MMP8MMP13CNR1 | |
| SCHEMBL1448661 | 1.00 | MMP2 (0.36) | MMP2MMP9MMP8MMP13CNR1 | |
| SCHEMBL1923234 | 1.00 | MMP2 (0.36) | MMP2MMP9MMP8MMP13CNR1 | |
| SCHEMBL4634013 | 0.98 | MMP2 (0.33) | MMP2MMP9MMP8MMP13CNR1 | |
| SCHEMBL1921532 | 0.93 | ELANE (0.33) | PDK2MEN1KMT2ATDP2 | |
| SCHEMBL12440909 | 0.92 | CNR1 (0.37) | MMP2MMP9MMP8MMP13CNR1 | |
| SCHEMBL1923373 | 0.92 | PDK2 (0.40) | MMP2MMP9MMP8MMP13CNR1 | |
| SCHEMBL1921668 | 0.92 | PDK2 (0.40) | MMP2MMP9MMP8MMP13CNR1 | |
| SCHEMBL16622910 | 0.92 | PDK2 (0.40) | MMP2MMP9MMP8MMP13CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1306131-B1 | Cross-coupling process using a catalyst comprising a cyclic nitrogen ligand | SUMITOMO CHEMICAL CO (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20060111593-A1 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2006-05-25 | — | — | US | disclosed |
| US-7041856-B2 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-05-09 | — | — | US | disclosed |
| US-20030162950-A1 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-08-28 | — | — | US | disclosed |
| EP-1306131-A2 | Cross-Coupling catalyst comprising a cyclic nitrogen ligand and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162950-A1 | Coupling catalyst and process using the same | NOD1, PYM1, C9 | MMP2 4810/4885MMP9 4454/4885MMP8 3519/4885 |
| US-20060111593-A1 | Coupling catalyst and process using the same | RPL22, C9, RBM22 | MMP2 4263/4885MMP9 3877/4885MMP8 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.